

Wipro

Estimate change	←
TP change	←→
Rating change	\leftarrow

Bloomberg	WPRO IN
Equity Shares (m)	10469
M.Cap.(INRb)/(USDb)	2952 / 34.1
52-Week Range (INR)	320 / 208
1, 6, 12 Rel. Per (%)	-4/6/9
12M Avg Val (INR M)	4169

Financials & Valuations (INR b)

Y/E Mar	FY25E	FY26E	FY27E
Sales	890	930	985
EBIT Margin (%)	17.0	16.7	16.8
PAT	127	129	137
EPS (INR)	12.0	12.3	13.0
EPS Gr. (%)	18.0	2.3	6.0
BV/Sh. (INR)	70.2	71.5	72.9
Ratios			
RoE (%)	17.1	17.4	18.1
RoCE (%)	13.0	13.6	14.2
Payout (%)	90.0	70.0	70.0
Valuations			
P/E (x)	23.4	22.9	21.6
P/BV (x)	4.0	3.9	3.9
EV/EBITDA (x)	14.4	13.9	14.6
Div Yield (%)	3.8	3.1	3.2

Shareholding pattern (%)

As On	Sep-24	Jun-24	Sep-23
Promoter	72.8	72.8	72.9
DII	8.7	8.3	8.0
FII	9.7	9.6	9.0
Others	8.8	9.4	10.0

FII Includes depository receipts

CMP: INR282 TP: INR290 (+3%) Neutral

Steady with little surprises

Strong margin execution, but 4Q guidance unexciting

Wipro (WPRO) reported 3QFY25 IT Services revenue of USD2.6b (0.1% QoQ) in constant currency (CC), above our estimate of a 1.0% QoQ decline. It posted an order intake of USD3.5b (down 1.3% QoQ), with a large deal TCV of USD0.96b (down 35% QoQ). EBIT margin of IT Services was 17.5% (est. 16.4%). EBITDA rose 4.0% QoQ/12.5% YoY to INR47b (est. INR45b). PAT stood at INR33.6b (+4.7% QoQ/+24.7% YoY), above our est. of INR30b. For 9MFY25, revenue declined 1.4%, whereas EBIT/PAT grew 11.4%/16.7% vs. 9MFY24. We expect revenues/EBIT/PAT to grow by 1.0%/11.1%/11.2% YoY in 4QFY25. We reiterate our Neutral rating as we view the current valuation as fair. Our TP of INR290 implies 22x FY27E EPS.

Our view: Robust quarter; no major overhang on 4Q margin

- WPRO delivered a steady performance in 3QFY25, driven by a strategic focus on key client segments (7 out of top 10 clients grew YoY CC) and growth in the Healthcare vertical. TCV reached USD3.5b in 3Q, with large deals contributing USD0.96b. A notable uptick in smaller- and medium-sized deals in 3Q aligns with peers' commentary, highlighting the growing momentum of short-cycle deals and signaling a recovery in discretionary spending.
- Growth was particularly strong in the US BFSI and Healthcare verticals, driven by a gradual recovery in discretionary spending. The company's focus on client mining and expanding its consulting business has further strengthened its deal pipeline, especially in the Americas.
- However, challenges remain in certain verticals and geographies. Its 4Q guidance is muted (-1.0% to 1.0% in CC), reflecting regional softness, particularly in Europe and APMEA. Manufacturing and E&U verticals continue to face client-specific headwinds, with no immediate signs of recovery expected.
- **Guidance:** Revenue from the IT Services segment is expected to grow in the range of -1.0% to 1.0% QoQ in CC terms.
- Margins: EBIT margins improved by 70bp to 17.5% in 3QFY25, driven by higher offshoring, increased utilization, and growth in fixed-price contracts. WPRO expects margins to remain stable in the range of 17-17.5% in 4Q with no major headwinds anticipated.

Beat on revenue and margins

- IT Services revenue at USD2.6b grew 0.1% QoQ in CC (reported USD revenue was down 1.2% QoQ), beating our estimate of a 1.0% QoQ decline.
- 4QFY25 revenue guidance is -1.0% to 1.0% in CC terms.
- Growth was driven by Healthcare (+6.7% QoQ CC), while BFSI/Consumer declined 1.9%/0.9% QoQ CC.
- IT Services EBIT margin was 17.5% (up 70bp QoQ), above our estimate of 16.4%.

Abhishek Pathak - Research Analyst (Abhishek.Pathak@MotilalOswal.com)

Research Analyst - Keval Bhagat (Keval.Bhagat@MotilalOswal.com) | Tushar Dhonde (Tushar.Dhonde@MotilalOswal.com)

- Americas 1 grew 3.9% QoQ CC, while Europe and APMEA declined by 2.7%/2.1%
 QoQ CC.
- 3Q TCV of USD3.5b was down 1.3% QoQ/7.3% YoY, while large TCV of USD0.96b was down 35% QoQ/up 6% YoY.
- Net utilization (excl. trainees) declined to 83.5% (vs. 86.4% in 2Q). Attrition (LTM) was up 80bp QoQ at 15.3%.
- Net profit rose 4.7% QoQ/24.7% YoY to INR33.6b (est. INR30b).

Key highlights from the management commentary

- While cost optimization remains a priority, the company is witnessing growing investments in AI. Demand is steadily increasing in the Americas.
- The consulting business is expanding, with improving demand environments in BFSI and Healthcare.
- Discretionary spending in BFSI and Capco has seen good traction in smaller deals.
- The top 25 clients, particularly in BFSI and Healthcare, are showing growth. The company plans to mine these accounts further through enhanced account management and delivery.
- 4Q guidance: -1% to 1% in CC.
- 3Q TCV was USD3.5b, including large deals worth USD0.96b, with strong traction across geographies. There has been an improvement in small- and medium-sized deals this quarter, with ACV conversion. The deal tenure has shortened.
- Europe performance remained soft. The company has established a new leadership team for deal conversions.
- Healthcare maintained growth momentum and is seeing expansion in client budgets, albeit slower than last year.
- The company plans to ramp up hiring in the coming quarters.
- WPRO has revised its capital allocation strategy, committing to returning over
 70% of net income to shareholders over a three-year block, starting in FY26.

Valuations and view

- We expect the company to deliver FY24-27E IT Services revenue CAGR of ~3.1%. We expect WPRO to clock ~17% operating margin in FY25, which should translate into a 7.5% CAGR in INR PAT over FY24-27E.
- We have raised our FY25E EPS by ~5% to factor in the margin beat and kept FY26E/FY27E EPS broadly unchanged after its 3Q print. We reiterate our Neutral rating as we view the current valuation as fair. Our TP of INR290 implies 22x FY27E EPS.

Quarterly Performance (IFRS)												(INR b)
Y/E March		F	Y24			FY2	5E		FY24	FY25E	Est.	VAS.
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE			3QFY25E	(% / bp)
IT Services Revenue (USD m)	2,779	2,713	2,656	2,657	2,626	2,660	2,629	2,627	10,805	10,542	2,620	0.3
QoQ (%)	-2.1	-2.3	-2.1	0.0	-1.2	1.3	-1.2	-0.1	-3.8	-2.4	-1.5	34bp
Overall Revenue (INR b)	228	225	222	222	220	223	223	224	896	890	222	0.7
QoQ (%)	-1.5	-1.4	-1.4	0.0	-1.1	1.5	0.1	0.4			-0.7	74bp
YoY (%)	6.0	-0.1	-4.4	-4.2	-3.8	-1.0	0.5	0.9	-0.9	-0.7	-0.2	75bp
GPM (%)	29.4	29.3	30.7	29.2	30.2	30.5	31.0	30.6	29.6	30.6	29.9	113bp
SGA (%)	14.2	14.6	16.0	13.2	13.7	13.6	13.8	13.0	14.5	13.5	13.4	36bp
EBITDA	42	42	42	44	44	46	47	48	170	185	45	6.5
EBITDA Margin (%)	18.4	18.8	19.0	19.7	20.2	20.5	21.3	21.3	19.0	20.8	20.1	114bp
IT Serv. EBIT (%)	16.0	16.1	16.0	16.4	16.5	16.8	16.0	17.6	16.4	17.1	16.4	-40bp
EBIT Margin (%)	15.1	14.8	14.8	15.9	16.4	16.7	17.5	17.5	15.2	17.0	16.3	114bp
Other income	3	2	3	3	4	6	6	3	11	18	3	88.6
ETR (%)	24.0	24.0	24.0	26.0	24.5	24.6	24.4	25.0	24.5	24.6	24.0	40bp
PAT	29	26	27	28	30	32	34	32	110	127	30	13.5
QoQ (%)	-6.6	-7.8	1.8	5.2	5.9	6.8	4.5	-6.0			-7.9	1243bp
YoY (%)	12.0	-0.5	-11.7	-7.8	4.6	21.3	24.5	11.2	-2.9	15.4	9.7	1480bp
EPS (INR)	2.6	2.5	2.6	2.7	5.7	3.1	3.2	3.0	10.2	12.0	2.8	13.5

Key performance indicators

Y/E March		FY	24		FY25				
	1Q	2Q	3Q	4Q	1Q	2Q	3Q		
Revenue (QoQ CC %)	-2.8	-2.0	-1.7	-0.3	-1.0	0.6	0.1		
Margins									
Gross Margin	29.4	29.3	30.7	29.2	30.2	30.5	31.0	29.6	
EBIT Margin	15.1	14.8	14.8	15.9	16.4	16.7	17.5	15.2	
Net Margin	12.6	11.8	12.1	12.8	13.7	14.4	15.0	12.3	
Operating metrics									
Headcount (k)	250	245	240	233	233	234	233	233	
Attrition (%)	17.3	15.5	14.2	14.2	14.1	14.5	15.3	14.2	
Utilization	83.7	84.5	84	86.9	87.7	86.4	83.5	84.8	
Key Verticals (QoQ CC %)									
BFSI	-4.3	-3.0	-4.3	2.1	0.5	2.7	-1.9	-8.9	
Retail	-3.5	-2.3	-1	-0.6	1.6	0.3	-0.9	-5.3	



Highlights from the management commentary

3QFY25 performance and demand outlook

- While cost optimization remains a priority, the company is witnessing growing investments in Al. Demand is steadily increasing in the Americas.
- The consulting business is expanding, with improving demand environments in BFSI and Healthcare.
- Discretionary spending in BFSI and Capco has seen good traction in smaller deals.
- The top 25 clients, particularly in BFSI and Healthcare, are showing growth. The company plans to mine these accounts further through enhanced account management and delivery.
- Bookings in the USD1-5m and USD5-20m account segments are growing at a faster pace.
- 4Q guidance: -1% to 1% in CC. Growth in the last two quarters has been above the midpoint of guidance.

17 January 2025

 Discretionary spending in the Americas is evident in BFSI, though it is not widespread at this point.

- Many clients are currently in the budgeting phase, with ongoing discussions to finalize agreements. Client hunting and account mining remain strategic priorities for the company.
- 3Q TCV was USD3.5b, including large deals worth USD0.96b, with strong traction across geographies. There has been an improvement in small- and medium-sized deals this quarter, with ACV conversion. The deal tenure has shortened.
- **BFSI:** Demonstrated the strongest traction in large deals. Impacted by furloughs in 3Q but still achieved YoY growth, driven by discretionary spending and the Capco business. An uptick in budgets is being observed.
- Healthcare: Maintained growth momentum. Budgets are expected to grow, although at a slower pace than last year. Broad-based growth was observed across payers, providers, pharmaceutical companies, and medical device manufacturers.
- Europe performance remained soft. The company has established a new leadership team for deal conversions.
- Attrition is expected to decline in the next quarter. The company plans to ramp up hiring in the coming quarters.
- The company has revised its capital allocation strategy, committing to returning over 70% of net income to shareholders over a three-year block, starting in FY26.

Margin outlook

- EBIT margin for the quarter stood at 17.5%, up 70bp QoQ. Key contributors to margin improvement in 3Q included better execution in core and consulting businesses, improved utilization, increased offshoring, and growth in fixed-price contracts.
- Overheads were consciously reduced. Wage hike impact is now absorbed.
- Reduced costs in third-party services also contributed to margin expansion. The company is seeing improved quality of revenue.
- For 4QFY25, margins are expected to remain in a narrow band (+/- 17.5%), with no significant headwinds anticipated.

Exhibit 1: Healthcare is seeing broad-based growth within its sub-segments

Verticals (QoQ CC, %)	3QFY22	1QFY22 1	QFY23 2	QFY233	QFY23 4	IQFY231	QFY242	2QFY243	3QFY244	QFY24	LQFY25 2	QFY253	QFY25
BFSI	4.1	3.4	2.4	3.6	-0.2	-2.4	-4.3	-3.0	-4.3	2.1	0.5	2.7	-1.9
Consumer Business Unit	5.2	4.2	5.0	5.5	0.6	-0.9	-3.5	-2.3	-1.0	-0.6	1.6	0.3	-0.9
Energy, Natural Resources & Utilities	-2.2	1.8	-1.0	6.6	2.8	5.9	-4.9	-5.3	0.7	-0.3	-6.3	-3.7	0.4
Health Business Unit	3.8	0.3	0.5	3.0	4.7	2.0	-1.3	1.4	7.5	1.2	-2.8	-0.5	6.7
Technology & Communications	0.9	3.6	0.8	1.5	-1.3	-2.7	0.1	5.8	-1.9	-6.0	-0.5	1.6	-0.6

Note: Company has clubbed Manufacturing in ENU w.e.f 3QFY25 Source: Company, MOFSL

Exhibit 2: Europe and APMEA region performance was weak in 3QFY25

Geographies (QoQ CC, %)	3QFY22	4QFY22	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25
Americas 1	5.2	3.1	3.1	2.9	1.3	-1.5	-1.1	1.0	2.0	-1.8	0.4	1.2	3.9
Americas 2	1.7	5.1	2.1	3.0	-0.9	-0.3	-4.2	-2.3	-1.3	1.9	-0.7	0.8	-0.6
Europe	2.3	2.3	1.2	5.6	2.4	-0.6	-3.4	-5.1	-4.3	-0.1	-1.4	-0.1	-2.7
APMEA	2.9	-0.3	2.2	6.7	-1.2	0.7	-1.9	-0.5	-5.4	-2.2	-4.2	0.3	-2.1

Source: Company, MOFSL

Valuations & View

- We expect the company to deliver FY24-27E IT Services revenue CAGR of ~3.1%. We expect WPRO to clock ~17% operating margin in FY25, which should translate into a 7.5% CAGR in INR PAT over FY24-27.
- We have raised our FY25E EPS by ~5% to factor in the margin beat and kept FY26E/FY27E EPS broadly unchanged after its 3Q print. We reiterate our Neutral rating as we view the current valuation as fair. Our TP of INR290 implies 22x FY27E EPS.


Exhibit 3: Revisions to our estimates

		Revised			Earlier			Change	
	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
INR/USD	84.1	85.0	85.0	84.1	85.0	85.0	0.0%	0.0%	0.0%
IT Services USD Revenue - m	10,542	10,895	11,541	10,555	11,044	11,698	-0.1%	-1.3%	-1.3%
Overall Growth (%)	(2.4)	3.4	5.9	(2.2)	4.5	5.9	-20bps	-110bps	0bps
EBIT margin - Overall (%)	17.0	16.7	16.8	16.3	16.3	16.4	70bps	40bps	40bps
EBIT margin - IT Services (%)	17.1	16.8	16.8	16.4	16.4	16.4	70bps	40bps	40bps
PAT (INR B)	127.2	129.0	136.8	121.1	128.6	136.3	5.0%	0.4%	0.3%
EPS	12.03	12.31	13.05	11.46	12.27	13.00	5.0%	0.4%	0.3%

Source: MOFSL, Company


Story in charts

Exhibit 4: WPRO achieved mid-point of its 3Q guidance



Source: Company, MOFSL

Exhibit 5: BFSI was down QoQ but uptick in budget is seen



Source: Company, MOFSL

Exhibit 6: Consumer showed decline in 3QFY25






Exhibit 7: EBIT margin up 70bp in 3QFY25




Source: Company, MOFSL

Exhibit 8: Utilization declined to 83.5%



Source: Company, MOFSL

Exhibit 9: Attrition increased by 80bp in 3QFY25



Source: Company, MOFSL

Operating metrics

Exhibit 10: Operating metrics

	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25
Verticals (%)									
Finance Solutions	34.9	34.2	33.9	33.6	32.7	33.5	34.0	34.8	34.1
Healthcare Life Sciences	12.0	12.2	12.2	12.7	13.9	14.1	13.9	13.6	14.7
Energy, Natural Resources, and Utilities*	11.4	12.3	12.0	18.6	18.5	18.5	17.6	17.0	16.9
Consumer	18.9	18.8	18.7	18.7	18.8	18.7	19.2	19.2	19.0
Technology	11.3	11.0	15.9	16.4	16.1	15.2	15.3	15.4	15.3
Geography (%)									
Americas 1	29.4	28.8	28.8	29.8	31.0	30.4	30.9	30.8	32.3
Americas 2	30.8	30.7	30.0	29.9	30.0	30.7	30.8	30.6	30.6
Europe	28.8	29.3	29.5	28.6	27.7	27.8	27.6	27.9	26.7
APMEA	11.0	11.2	11.7	11.7	11.3	11.1	10.7	10.7	10.4
Customer size distribution (TTM)									
Over USD100m	19	19	21	22	22	22	22	21	18
Over USD75m	29	29	28	28	31	32	29	30	30
Over USD50m	52	53	51	51	46	45	43	42	42
Over USD20m	119	117	123	122	121	116	117	117	114
Over USD10m	204	210	207	207	203	205	192	186	187
Over USD5m	312	315	319	313	305	301	301	297	290
Over USD3m	440	436	444	437	430	409	407	411	403
Over USD1m	755	766	769	774	750	741	735	733	722
Customer metrics									
Revenue from existing customers (%)	96.9	96.6	99.6	99.1	98.8	97.8	99.7	99.4	98.8
Number of new customers	82	63	65	49	55	60	43	28	63
Total number of active customers	1484	1441	1444	1393	1349	1371	1364	1342	1299
Employee metrics									
Closing headcount – IT Services (k)	262	259	250	245	240	233	233	234	233
Sales and support staff – IT Services (k)	17	17	17	17	16	0	0	0	0
Utilization									
Net utilization (excluding trainees, %)	79.7	81.7	83.7	84.5	84.0	86.9	87.7	86.4	83.5
Attrition									
Voluntary TTM	21.2	19.4	17.3	15.5	14.2	14.2	14.1	14.5	15.3
Customer concentration (%)									
Top customer	3.2	3.2	3.1	3.0	3.0	3.8	4.0	4.1	4.5
Top five	13.3	12.6	12.5	12.3	12.1	13.4	13.6	14.0	14.3
Top 10	21.2	20.2	20.5	20.6	20.5	22.0	22.5	22.9	23.7

Note:* Effective 3QFY25, the company has merged Manufacturing in ENU vertical for reporting; Source: MOFSL, Company

Financials and valuations

Y/E March	2020	2021	2022	2023	2024	2025E	2026E	2027E
Sales	610	619	791	905	896	890	930	985
Change (%)	4.2	1.5	27.7	14.4	-0.9	-0.7	4.4	5.9
Operating Costs	436	423	556	645	631	618	650	688
Gross Profit	174	196	235	259	266	272	280	297
SG&A	69	73	97	120	130	121	125	132
EBITDA	126	151	169	173	170	185	191	202
% of Net Sales	20.6	24.3	21.4	19.1	19.0	20.8	20.5	20.6
Depreciation & Amort.	21	28	31	33	34	34	35	37
EBIT	105	123	138	140	136	151	155	165
% of Net Sales	17.2	19.8	17.5	15.4	15.2	17.0	16.7	16.8
Other Income	17	16	13	8	11	18	17	17
РВТ	123	139	151	148	147	170	172	182
Tax	25	30	29	34	36	42	42	45
Rate (%)	20.2	21.8	19.1	23.0	24.5	24.6	24.5	24.5
Extraordinary items	0	0	0	0	0	0	0	0
Minority Interest	0	1	0	0	1	1	1	1
Adjusted PAT	97	108	122	114	110	127	129	137
Change (%)	8.0	11.0	13.2	-7.1	-2.9	15.4	1.5	6.0
Balance Sheet Y/E March	2020	2021	2022	2023	2024	2025E	2026E	(INR b) 2027E
								
Share Capital Reserves	11 546	11 542	11 647	770	10 739	10 724	10 737	751
Net Worth	557	553	658	770 781	750	734	747	762
Minority Interest & others	38	41	56	66	88	55	57	60
Loans		83	152	150	141	131	121	111
Capital Employed	674		132			131	121	111
Capital Elliployeu		677	966	997	070	020	026	024
Gross Block		677	866	997	979	920	926	934
Gross Block	268	299	338	369	395	413	432	451
Less : Depreciation	268 170	299 198	338 228	369 262	395 296	413 330	432 365	451 402
Less : Depreciation Net Block	268 170 98	299 198 102	338 228 110	369 262 107	395 296 100	413 330 84	432 365 67	451 402 49
Less : Depreciation Net Block Investments	268 170 98 11	299 198 102 12	338 228 110 20	369 262 107 22	395 296 100 23	413 330 84 23	432 365 67 23	451 402 49 23
Less : Depreciation Net Block Investments Intangible Assets	268 170 98 11 147	299 198 102 12 152	338 228 110 20 291	369 262 107 22 351	395 296 100 23 349	413 330 84 23 349	432 365 67 23 349	451 402 49 23 349
Less : Depreciation Net Block Investments Intangible Assets Other non-current assets	268 170 98 11 147 41	299 198 102 12 152 42	338 228 110 20 291 38	369 262 107 22 351 35	395 296 100 23 349 31	413 330 84 23 349 50	432 365 67 23 349 52	451 402 49 23 349 55
Less: Depreciation Net Block Investments Intangible Assets Other non-current assets Curr. Assets	268 170 98 11 147 41 520	299 198 102 12 152 42 523	338 228 110 20 291 38 621	369 262 107 22 351 35 661	395 296 100 23 349 31 651	413 330 84 23 349 50 661	432 365 67 23 349 52 691	451 402 49 23 349 55 727
Less: Depreciation Net Block Investments Intangible Assets Other non-current assets Curr. Assets Debtors	268 170 98 11 147 41 520 130	299 198 102 12 152 42 523 121	338 228 110 20 291 38 621 176	369 262 107 22 351 35 661 187	395 296 100 23 349 31 651 174	413 330 84 23 349 50 661 182	432 365 67 23 349 52 691 190	451 402 49 23 349 55 727 201
Less: Depreciation Net Block Investments Intangible Assets Other non-current assets Curr. Assets Debtors Inventories	268 170 98 11 147 41 520 130	299 198 102 12 152 42 523 121	338 228 110 20 291 38 621 176	369 262 107 22 351 35 661 187	395 296 100 23 349 31 651 174	413 330 84 23 349 50 661 182	432 365 67 23 349 52 691 190	451 402 49 23 349 55 727 201
Less: Depreciation Net Block Investments Intangible Assets Other non-current assets Curr. Assets Debtors Inventories Cash & Bank Balance	268 170 98 11 147 41 520 130 2	299 198 102 12 152 42 523 121 1 170	338 228 110 20 291 38 621 176 1	369 262 107 22 351 35 661 187 1	395 296 100 23 349 31 651 174 1	413 330 84 23 349 50 661 182 1	432 365 67 23 349 52 691 190 1	451 402 49 23 349 55 727 201 1
Less: Depreciation Net Block Investments Intangible Assets Other non-current assets Curr. Assets Debtors Inventories Cash & Bank Balance Adv., Other Current Assets	268 170 98 11 147 41 520 130 2 144	299 198 102 12 152 42 523 121 1 170 55	338 228 110 20 291 38 621 176 1 104	369 262 107 22 351 35 661 187 1 92	395 296 100 23 349 31 651 174 1 97	413 330 84 23 349 50 661 182 1 74	432 365 67 23 349 52 691 190 1 74	451 402 49 23 349 55 727 201 1 74
Less: Depreciation Net Block Investments Intangible Assets Other non-current assets Curr. Assets Debtors Inventories Cash & Bank Balance Adv., Other Current Assets Investments	268 170 98 11 147 41 520 130 2 144 54 190	299 198 102 12 152 42 523 121 170 55 176	338 228 110 20 291 38 621 176 1 104 98 242	369 262 107 22 351 35 661 187 1 92 72 309	395 296 100 23 349 31 651 174 1 97 68	413 330 84 23 349 50 661 182 1 74 73	432 365 67 23 349 52 691 190 1 74 76 351	451 402 49 23 349 55 727 201 1 74 79
Less: Depreciation Net Block Investments Intangible Assets Other non-current assets Curr. Assets Debtors Inventories Cash & Bank Balance Adv., Other Current Assets	268 170 98 11 147 41 520 130 2 144	299 198 102 12 152 42 523 121 1 170 55	338 228 110 20 291 38 621 176 1 104	369 262 107 22 351 35 661 187 1 92	395 296 100 23 349 31 651 174 1 97	413 330 84 23 349 50 661 182 1 74	432 365 67 23 349 52 691 190 1 74	451 402 49 23 349 55 727 201 1 74

Financials and valuations

Ratios								
Y/E March	2020	2021	2022	2023	2024	2025E	2026E	2027E
Basic (INR)								
EPS	8.2	9.4	11.0	10.4	10.2	12.0	12.3	13.0
Cash EPS	10.1	12.0	14.0	13.4	13.5	15.4	15.7	16.6
Book Value	47.8	49.0	60.2	71.3	70.9	70.2	71.5	72.9
DPS	0.5	0.5	3.0	0.5	0.0	10.8	8.6	9.1
Payout %	113.9	93.3	26.9	4.8	1.6	90.0	70.0	70.0
Valuation (x)								
P/E	34.4	30.1	25.7	27.2	27.7	23.4	22.9	21.6
Cash P/E	27.9	23.6	20.2	21.1	20.8	18.4	18.0	17.0
EV/EBITDA	24.1	19.4	17.1	16.4	16.0	14.4	13.9	14.6
EV/Sales	5.0	4.7	3.7	3.1	3.0	3.0	2.8	3.0
Price/Book Value	5.9	5.8	4.7	4.0	4.0	4.0	3.9	3.9
Dividend Yield (%)	0.2	0.2	1.1	0.2	0.0	3.8	3.1	3.2
Profitability Ratios (%)								
RoE	17.3	19.4	20.2	15.8	14.4	17.1	17.4	18.1
RoCE	13.7	16.0	16.3	12.8	11.3	13.0	13.6	14.2
Turnover Ratios								
Debtors (Days)	78	72	81	75	71	74	74	74
Asset Turnover (x)	0.7	0.8	0.8	0.8	0.8	0.8	0.8	0.8
Leverage Ratio								
Debt/Equity Ratio(x)	0.1	0.2	0.2	0.2	0.2	0.2	0.2	0.1

Cash Flow Statement								(INR b)
Y/E March	2020	2021	2022	2023	2024	2025E	2026E	2027E
CF from Operations	124	125	147	145	158	161	164	174
Cash for Wkg. Capital	-24	23	-36	-15	19	7	0	-2
Net Operating CF	101	148	111	131	176	168	164	172
Net Purchase of FA	-22	-19	-19	-14	-6	-18	-19	-20
Other change in investments	56	27	-205	-70	18	-20	-20	-20
Net Cash from Invest.	34	8	-224	-84	12	-38	-39	-40
Issue of Shares/Other adj	0	0	0	0	0	0	0	0
Proceeds from LTB/STB	-143	-122	53	-28	-177	-20	-20	-20
Dividend Payments	-8	-6	-7	-33	-6	-132	-105	-112
Net CF from Finan.	-151	-129	47	-61	-183	-153	-126	-132
Free Cash Flow	78	129	91	116	170	150	145	153
Net Cash Flow	-16	26	-67	-14	5	-23	0	0
Forex difference	2	-1	1	2	0	0	0	0
Opening Cash Bal.	157	142	168	102	90	95	73	72
Add: Net Cash	-14	26	-66	-12	5	-23	0	0
Closing Cash Bal.	142	168	102	90	95	73	72	73

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

NOTES

Explanation of Investment Rating				
Investment Rating	Expected return (over 12-month)			
BUY	>=15%			
SELL	< - 10%			
NEUTRAL	> - 10 % to 15%			
UNDER REVIEW	Rating may undergo a change			
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation			

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures:

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL),NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motifal Oswal Financial Services Ltd. are available on the website at http://onlinereports.mot

Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx

MOFSL, it's associates, Research Analyst or their relatives may have any financial interest in the subject company. MOFSL and/or its associates and/or Research Analyst or their relatives may have actual beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance. MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may have any other potential conflict of interests at the time of publication of the research report or at the time of public appearance, however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

In the past 12 months, MOFSL or any of its associates may have:

- received any compensation/other benefits from the subject company of this report
- b)
- managed or co-managed public offering of securities from subject company of this research report, received compensation for investment banking or merchant banking or brokerage services from subject company of this research report, c)
- received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report. d)
- MOFSL and it's associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.
- Subject Company may have been a client of MOFSL or its associates during twelve months preceding the date of distribution of the research report.
- Research Analyst may have served as director/officer/employee in the subject company.
- MOFSL and research analyst may engage in market making activity for the subject company.

MOFSL and its associate company(ies), and Research Analyst and their relatives from time to time may have:

a) a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein.

(b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures. To enhance transparency, MOFSL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Disclosure of Interest Statement	1	/ipro			
Analyst ownership of the stock		No			

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Financial Services Limited (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

MOTILAL Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services

17 January 2025 11

described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co. Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act of Singapore .Accordingly, if a Singapore person is not, or ceases to be, such an investor, they must immediately discontinue any use of this Report and inform MOCMSPL.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN .: 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.